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Abstract
Background: There is increasing evidence that the toll-like receptor 3 (TLR3) is an interesting target for anti-cancer 
therapy. Unfortunately, most laboratory investigations about the impact of TLR3 stimulation on human malignant cells 
have been performed with very high concentrations - 5 to 100 μg/ml - of the prototype TLR3 ligand, poly(I:C). In a 
previous study focused on a specific type of human carcinoma - nasopharyngeal carcinoma - we have shown that 
concentrations of poly(I:C) as low as 100 ng/ml are sufficient to induce apoptosis of malignant cells when combined to 
a pharmacological antagonist of the IAP family based on Smac mimicry.
Methods: This observation prompted us to investigate the contribution of the IAP family in cell response to poly(I:C) in 
a variety of human malignant cell types.
Results: We report a rapid, intense and selective increase in c-IAP2 protein expression observed under stimulation by 
poly(I:C)(500 ng/ml) in all types of human malignant cells. In most cell types, this change in protein expression is 
underlain by an increase in c-IAP2 transcripts and dependent on the TLR3/TRIF pathway. When poly(I:C) is combined to 
the IAP inhibitor RMT 5265, a cooperative effect in apoptosis induction and/or inhibition of clonogenic growth is 
obtained in a large fraction of carcinoma and melanoma cell lines.
Conclusions: Currently, IAP inhibitors like RMT 5265 and poly(I:C) are the subject of separate therapeutic trials. In light 
of our observations, combined use of both types of compounds should be considered for treatment of human 
malignancies including carcinomas and melanomas.
Background
Toll-like receptor 3, a membrane receptor of double
strand RNAs, is a major effector of the immune response
against viral pathogens at the cellular and systemic level.
It is involved in early activation of NK and dendritic cells.
It is also expressed in a wide range of non-immune cells
where it plays a key role in the induction of interferon
response [1]. TLR3 is frequently expressed by malignant
cells of various types and there are several observations
suggesting that it can be targeted for therapeutic purpose
[2,3]. At least one clinical trial has shown a therapeutic
benefit for breast carcinoma patients treated with the
synthetic TLR3 agonist poly(A/U) [4]. On the other hand,
several in vitro studies have reported apoptosis induction
in malignant cells treated with the synthetic TLR3-ago-
nist, poly(I:C). However, these results were obtained
using very high concentrations of this agent in the range
of 10 to 100 μg/ml [5-9]. Such concentrations are proba-
bly incompatible with doses of synthetic ligands accept-
able for patient treatment. One of our previous study
focused on nasopharyngeal carcinoma has opened news
perspectives in this field [10]. Nasopharyngeal carcinoma
or NPC is a human epithelial tumor whose malignant
cells are latently infected by the Epstein-Barr virus (EBV).
Using our experimental model of NPC, we could demon-
strate that massive caspase-dependent apoptosis was
induced in NPC cells by poly(I:C) at a low concentration
(500 ng/ml) when it was combined to RMT 5265 (100
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[10].
Inhibitor of apoptosis proteins (IAP) are a class of regu-
latory proteins, with mainly anti-apoptotic properties,
characterized by the presence of one to three domains
known as baculoviral IAP repeat (BIR) domains [11].
Among these IAP proteins, X-linked IAP (XIAP) is a
direct inhibitor of caspase activity. It is produced in large
amounts in all cell types and is often regarded as a house-
keeping protein [11]. Cellular IAP-1 (cIAP-1) and cIAP-2
have more complex regulatory functions, many of these
functions involving their E3 ubiquitin-ligase activity [12-
14]. Recent studies have emphasized their connection
with TNF-receptor signaling and NF-kB activation [14-
16]. They are expressed at various levels in cancer cells
depending on the tumor type [10]. Second mitochondria-
derived activator of caspase (Smac) is an endogenous
antagonist of IAP protein [17]. In its dimeric form, Smac,
via its AVPI tetrapeptide binding motif, binds the BIR
domains of XIAP, c-IAP1 and 2. It causes proteasome-
dependent degradation of c-IAP1 and c-IAP2 [17]. RMT
5265 is the prototype of a new class of anticancer drugs
called Smac mimetics [18]. This polycyclic compound
was designed for spatial mimicry of the AVPI motif of the
Smac protein. It is cell permeable and specifically binds c-
IAP1, c-IAP2 and XIAP, triggering rapid proteasome-
dependent degradation of c-IAP1 and c-IAP2 [10,18]. It is
also suspected to antagonize the functions of XIAP [18].
Our previous study on NPC cells provided the proof of
principle 1) that synthetic TLR3 ligands could be active
on malignant cells at much lower concentrations than
previously reported (below 1 μg/ml); 2) that the IAP fam-
ily of proteins was very important to modulate cell
response to TLR3 stimulation and 3) that combinations
of TLR3 ligands with IAP inhibitors were susceptible to
provide a therapeutic benefit [10]. However NPC cells
have unique biological features, for example a low fre-
quency of p53 mutations, in addition to a latent EBV-
infection in virtually 100% of the cases [19]. Therefore, it
was important to investigate the role of IAPs in other
types of malignant cells subjected to TLR3 stimulation.
Using a panel of various human carcinoma and mela-
noma cell lines, we decided to address the following ques-
tions: 1) What is the influence of a TLR3 synthetic ligand
on the status of the IAP proteins? 2) Can we enhance the
pro-apoptotic effect of a TLR3 ligand by combination
with an IAP inhibitor?
We report that the basal concentration of c-IAP2 is at a
low level in a majority of malignant cell types, in constrast
with our previous observations in NPC cells. However,
stimulation of TLR3 by the synthetic ligand poly(I:C)
induces a rapid, substantial and specific increase in c-
IAP2 protein content, in all malignant cells tested. This
increase is, at least to a large extent, explained by a tran-
scriptional effect. When poly(I:C) was combined with the
IAP inhibitor RMT 5265, we observed a cooperative
effect in apoptosis induction and/or inhibition of clono-
genic growth in a wide range of cancer cells.
Methods
Cell lines
The following malignant cell lines were used: HeLa (epi-
thelial, cervix carcinoma); T1, SK29 and Rosi (melano-
mas); SKOV3 and IGR-OV1 (ovarian carcinomas);
LNCaP (prostatic carcinoma) [16,20]. MRC5 cells are
non-malignant human fibroblasts purchased from
Biomerieux (Marcy l'Etoile, France). The NP69 cell line
was obtained by SV40 infection of epithelial cells derived
from a piece of non-malignant human nasopharyngeal
mucosa [21]. NP69 cells were grown in KGF keratinocyte
medium supplemented with 10% fetal calf serum (FCS).
LNCaP, SK29, Rosi, IGR-OV1 and MRC5 cells were con-
tinuously grown in RPMI 1640 medium (Gibco-Invitro-
gen, Cergy Pontoise, France) supplemented with 10%
FCS, SKOV3 cells were grown in Mc Coy's 5A medium
(Gibco-Invitrogen) supplemented with 10% FCS and 2%
sodium bicarbonate, T1 cells in RPMI 1640 medium sup-
plemented with 10% FCS and 1% sodium pyruvate and
HeLa cells in Dulbecco's modified Eagle medium
(DMEM) (Gibco-Invitrogen) supplemented with 5% FCS.
Preparation of cell suspensions from tumor biopsies
Fragments of tumor biopsies were obtained after written
informed consent from two patients treated at the Insti-
tut de Cancérologie Gustave Roussy (Villejuif, France).
Patient A, male, aged 42, had a well differentiated
squamous cell carcinoma of the larynx, staged T2N0M0.
Patient B, male, aged 52 had a differentiated squamous
cell carcinoma of the oral cavity staged T4N2bM0. A few
minutes after collection, these tumor fragments were
minced in small pieces (1 to 2 mm diameter) and incu-
bated sequentially 1) in a solution of trypsin (1.25 mg/
ml)(Sigma, St Quentin Fallavier, France) in DPBS (Dul-
becco Phosphate Buffered Saline - Invitrogen) at 4°C for
90 min with agitation; 2) then in a solution of collagenase
(4 mg/ml)(type 2, Worthington) and DNAse (10 μg/
ml)(Sigma) in RPMI culture medium with 20% fetal calf
serum at 37°C for 3 hours. Tumor cells were then dis-
persed by energetic pipet aspirations and releases,
washed, filtered through a 70 μm cell strainer, counted
and seeded in 24-well culture plates at a density of 0.5
million/well.
Treatments of cells with pharmacological reagents
The polycyclic C2-symmetric (40 carbon atoms) com-
pound RMT 5265, which mimics the three-dimensionnal
structure of the Smac/Diablo N-terminal tetrapeptide,
has been previously described [18]. HS4044 or control
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alanine group; it was used as a negative control [18]. Both
reagents were dissolved in DMSO. Agonists of TLR3
(poly(I:C)) and TLR9 (type C CpG) were obtained from
InvivoGen (Toulouse, France). Bafilomycin A1 (endo-
somal acidification inhibitor) and 2-Aminopurine (PKR
inhibitor) were purchased from Sigma.
RNA interference
Expression of proteins was knocked down using the fol-
lowing siRNA: TRIF (TICAM1) (1: HSS152364; 2:
HSS152365; 3: HSS175528), TLR3 (1: HSS110815; 2:
HSS110817), c-IAP2 (HSS100561), XIAP (HSS100565).
These siRNA and a negative control (NS; ref. 1390109)
were purchased from Invitrogen. Transfections were car-
ried our using Oligofectamine (Invitrogen). The final
concentration of siRNAs in the culture medium was 100
nM for 4 h and 50 nM for the next 44 h. The impact on
protein expression was assessed by western blotting, 48 h
or 72 h after the initiation of transfection.
RNA extraction, reverse transcription and polymerase 
reaction
Total RNA was extracted from cultured cells with the
RNeasy extraction kit (Qiagen, Valencia, CA). Total RNA
(1 μg) was reverse-transcribed using the Protoscript First
Strand cDNA Synthesis Kit (New England BioLabs, Ips-
wich, MA). Real-time PCR was performed in a 25 μl reac-
tion volume, containing 25 ng of cDNA template, 10
pmol of each primer and 12.5 μl of TaqMan Universal
PCR Master Mix (Applied Biosystems, Foster City, CA).
The following sets of primers and probes were purchased
from Applied Biosystems (TaqMan Gene Expression sys-
tem): BIRC3 (HS00154109_m1), TLR3 (HS01551078_
m1), TLR4 (HS00152939_m1), TLR9 (HS00370913_s1),
and GAPDH (HS99999905_m1). Amplification reactions
were performed in an Applied Biosystems Abi Prism
7000 Sequence Detection System. Data from RQ-PCR
were analysed using the comparative CT method with
GADPH as an endogenous reference.
Cell Growth Assays
Clonogenic growth of various cell types was assessed by
plating cells at low density in six well plates. Initial cell
densities were established for each cell type on the basis
of pilot experiments varying from 2000 (NP69) to 5000
(others cell types) per well in six well plates. After 2 to 4
weeks of culture, cell colonies were stained with a solu-
tion of crystal violet. Dried plates were then scanned and
digitized to allow optical magnification and precise
counting of cell colonies.
Assessment of Apoptosis and Caspase Activation
Apoptosis was assessed quantitatively by determining the
sub-G1 DNA content in ethanol-fixed cells, stained with
propidium iodide and analyzed using a Becton Dickinson
FACScalibur flow cytometer and the CellQuest Pro soft-
ware. Alternatively, apoptosis was evaluated by the detec-
tion of the cleavage of poly (ADP-ribose) polymerase
(PARP) by western blot analysis performed on total cell
protein extracts. The activities of caspases-3/7 and cas-
pase-8 were measured with the Caspases-Glo 3/7 and
Caspases-Glo 8 Assay kits, respectively (Promega, Lyon,
France). These assays are based on the cleavage of lumi-
nogenic substrates containing the amino-acid sequences
Z-DEVD and Z-LETD, respectively.
Cell protein extraction and western blot analysis
Proteins from cultured cells were extracted by lysis in
RIPA buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA,
0.5% sodium DOC, 0.5% NP40, 0.1% SDS) supplemented
with a protease inhibitor cocktail (Complete, Roche,
Meylan, France). They were separated by SDS-PAGE and
transferred to PVDF membranes (Immobilon, Millipore,
Billerica, CA) by electroblotting at 4°C for 90 minutes at
90 V or overnight at 45 V. The antibodies used for west-
ern blotting were mouse monoclonal antibodies directed
against human c-IAP2, XIAP and c-IAP1, obtained from
BD Biosciences (reference 552782, 610763 and 556533,
respectively; Le Pont de Claix, France). The other mouse
monoclonal antibodies used were specific for FLICE-like
inhibitory protein (FLIP) (Alexis Biochemical, ref. 804-
428; San Diego, CA), PARP (Santa Cruz Biotechnology;
ref. 53643; Heidelberg, Germany), TRIF (Cell Signalling,
ref. 4596; Danvers, MA), caspase-8 (Cell Signaling, ref.
9746), TLR3 (R&D systems ref. MAB1487; Lille, France),
β-actin (Millipore, Billerica, CA, ref. MAB1501) and
tubulin-α (Sigma, ref. T5168). Blots were incubated with
a secondary peroxidase-conjugated antibody and chemi-
luminescent detection was done using the Immobilon
Western Chemiluminescent HRP Substrate (Millipore,
Billerica, CA).
Statistics
Results of real-time PCR, colony assays and caspase
assays were given as the means +/- standard deviation
(SD). Statistical significance was assessed using a two-
tailed Student's t test for comparison of 2 experimental
conditions. When making comparisons involving multi-
ple experimental conditions we used the ANOVA test
completed by the Tukey test (bilateral) in the XLSTAT
software (confidence interval 95%).
Results
TLR3 transcripts are constitutively expressed in various 
types of human malignant cells
TLR3 expression has been reported in a wide range of
human malignant cells [5,6,8]. To confirm this observa-
tion, TLR3 messenger RNAs were analyzed by quantita-
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including one melanoma (T1), two ovarian carcinomas
(IGR-OV1 and SKOV3), one endocervical carcinoma
(HeLa), one prostate carcinoma (LNCaP). Two human
control cell lines were analyzed in parallel: a human dip-
loid fibroblast cell line (MRC5) and an SV40-immortal-
ized non-tumorigenic cell line derived from human
nasopharyngeal epithelial cells (NP69). As shown in Fig-
ure 1A, transcripts of TLR3 were readily detected in all 5
malignant cell lines at a higher level than in non-tumori-
genic MRC5 and NP69 cells. The distribution of TLR4
and 9 transcripts was quite different. There were homo-
geneous high levels of TLR9 transcripts in tumorigenic
and non-tumorigenic cells and a more restricted expres-
sion of TLR4 with high levels in T1 and NP69 cells. In
some experimental systems, double strand RNA has been
shown to induce a positive feed-back on TLR3 expression
[22]. We investigated whether the same positive feed-
back mechanism could happen in our cell lines under
treatment by poly(I:C) at 500 ng/ml for 16 h. As shown in
Figure 1B, we observed almost no changes in TLR4 and
TLR9 transcript levels. In contrast, TLR3 expression was
enhanced more than 2 fold in 4 of the 5 malignant cell
lines and only slightly modified in MRC5 and NP69. The
increase in TLR3 messenger RNAs resulted in an increase
in protein expression as shown in Figure 1C. In summary,
TLR3 transcripts are abundant and highly inducible in
various types of human malignant cells whereas they are
at a low level and not inducible in two different types of
human non-malignant cells.
Poly(I:C) treatment increases c-IAP2 protein concentration 
in various types of human malignant cells
In our previously published tumor model - nasopharyn-
geal carcinoma (NPC) - c-IAP2 cell concentrations were
uniformly very high whereas c-IAP1 was consistently
undetectable [10]. In contrast, we knew from preliminary
experiments that the basal levels of c-IAP1 and c-IAP2
were highly variable in various types of non-NPC malig-
nant cells. Therefore we decided to assess the status of
several IAP proteins - c-IAP1, c-IAP2 and XIAP - in basal
conditions and under treatment by poly(I:C). The panel
of cell lines described in the previous experiment com-
pleted by two additional melanoma cell lines (SK29 and
Rosi) was subjected to stimulation by poly(I:C), 500 ng/
ml for 16 h. Then the cell concentrations of IAPs were
compared by western blotting in the absence or in the
presence of poly(I:C). As shown in Figure 2A, in basal
conditions, c-IAP2 was at a low level of concentration in
most malignant cell types. However, in the presence of
poly(I:C), its concentration was substantially increased in
all types of malignant cells with amplitudes varying from
2 (SKOV3) to 10 fold (SK29). In contrast c-IAP2 concen-
trations were not modified in NP69 and MRC5 (in the lat-
ter, c-IAP2 remained undetectable). Simultaneously, the
levels of c-IAP1 and XIAP concentrations were not sig-
nificantly modified except a 70% increase in XIAP con-
centration in the SK29 cell line. The dose-effect
relationships and kinetics of the increase in c-IAP2 pro-
tein expression was investigated in HeLa cells. An
increase in c-IAP2 protein concentration was detectable
with concentrations of poly(I:C) as low 50 ng/ml; it was
dose-dependent from 50 to 250 ng/ml and then reached a
plateau (Figure 2B). Stimulation by a TLR9 agonist in the
same range of concentrations had absolutely no effect on
c-IAP2 concentration. c-IAP1 concentrations were not
modified either by poly(I:C) or the TLR9 agonist. In
terms of kinetics, the increase in c-IAP2 cell concentra-
tion was detectable between 4 and 8 hours with a peak
between 16 h and 24 h (Figure 2C). Overall, these data
demonstrate a specific increase in c-IAP2 cell concentra-
tions induced by treatment with poly(I:C). This change is
restricted to malignant cell types. In HeLa cells it is maxi-
mal between 16 h and 24 h and detectable with concen-
trations of poly(I:C) as low as 50 ng/ml. To provide
evidence that the stimulatory effect of poly(I:C) on c-
IAP2 expression was not restricted to malignant cell lines
permanently propagated in vitro, we prepared tumor cells
derived from Head and Neck squamous cell carcinomas
and used them in short term primary cultures. These
cells directly explanted from fresh tumors were treated
with poly(I:C) (500 ng/ml) for 16 h. As shown in Figure
2D, we observed the same dramatic increase in c-IAP2
concentration.
Poly(I:C) treatment specifically enhances c-IAP2 expression 
through TLR3 stimulation
In order to understand how the cell concentration of c-
IAP2 was increased by poly(I:C), we investigated its influ-
ence on the transcription of the c-IAP2 gene (BIRC3) in 5
malignant and 2 non-malignant cell types by quantitative
reverse-PCR. Under stimulation by poly(I:C) 500 ng/ml, a
statistically significant increase in cell concentrations of
the BIRC3 transcripts was observed in 4 of 5 malignant
cell types contrasting with virtually no increase in the
non-malignant cell types (Figure 3A). In terms of kinetics,
HeLa cells showed a dramatic increase in the amount of
BIRC3 transcripts detected as early as 2 hours after the
onset of the treatment by poly(I:C) with a plateau reached
at 16 hours (Figure 3B). There are several known cellular
receptors or sensors for double-strand RNA including
TLR3 or PKR (protein kinase R) [23]. PKR is selectively
inhibited by 2-aminopurine (2-AP) whereas TLR3 is
inhibited by bafilomycine A1 (BFA). BFA is an inhibitor
of the endosomal acidification pathway which prevents
the adequate function of TLR3 within the endosomal
compartment [23]. HeLa cells were stimulated by
poly(I:C) (500 ng/ml) or TNF-α (20 ng/ml) which is a
Friboulet et al. BMC Cancer 2010, 10:327
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Figure 1 Assessment of TLR 3, 4 and 9 messenger RNAs and TLR3 protein in a panel of human cell lines in basal conditions and under stim-
ulation by poly(I:C). A) Relative expression levels of TLR3, 4 and 9 transcripts in basal conditions. Levels of mRNAs in HeLa cells were chosen as a ref-
erence and arbitrarily set at 1. B) TLR mRNA relative increase in expression under stimulation by poly(I:C) (500 ng/ml) for 16 h. For each cell type, the 
basal level of expression was taken as a reference and set at 1. C) Western blot detection of the TLR3 protein in HeLa cells treated for 16 h with increas-
ing concentrations of poly(I:C)(from 250 ng/ml to 2 μg/ml). β-actin staining was used to control protein loading. Data presented in A), B) and C) are 
representative of at least two similar experiments. The stars indicate a statistical difference from respective controls (p < 0.05).
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Page 6 of 14known inducer of c-IAP2 gene expression, in the absence
or in the presence of inhibitors (BFA or 2-AP)(Figure 3C)
[24]. BFA combined with poly(I:C) had a dramatic reduc-
ing effect on the amount of BIRC3 transcripts contrasting
with almost no effects on BIRC3 transcription induced by
TNF-α. The PKR inhibitor 2-AP had partial decreasing
effects on the amount of BIRC3 transcripts under both
poly(I:C) and TNF-α stimulation. The TRIF protein is a
key adaptor molecule of TLR3 signal transduction
whereas it is not required for signalling by other sensors
Figure 2 Status of the IAP proteins in a panel of malignant and non-malignant cell types in basal conditions and under stimulation by the 
poly(I:C). A) Variations in IAP protein concentrations in basal conditions and after 16 h of stimulation by poly(I:C) 500 ng/ml. The c-IAP1, c-IAP2 and 
XIAP relative concentrations were assessed by iterative staining of blotted membranes. β-actin was used as a loading control for density measure-
ments. B) Exploration of the dose-effects relationships in c-IAP2 induction in HeLa cells treated for 16 h by poly(I:C) (TLR3 agonist) or CpG DNA (TLR9 
agonist) at concentrations increasing from 50 to 2000 ng/ml. The same membrane was stained successively with anti-c-IAP2, c-IAP1 and β-actin. C) 
Western blot analysis of HeLa cells treated with poly(I:C) 500 ng/ml for increasing time intervals from 1 h to 48 h. The same membrane was stained 
successively with anti-c-IAP2, c-IAP1 and β-actin. D) Increase in c-IAP2 protein expression in malignant cells directly explanted in vitro from fresh hu-
man tumors. Cells were prepared for short term primary cultures from tumor biopsy fragments obtained from 2 patients designated A and B. These 
patients were referred for Head and Neck squamous cell carcinomas (see Methods section). Cells were incubated with poly(I:C) immediately after tu-
mor dispersion for 16 h and collected for protein extraction and western blot analysis of c-IAP2 and β-actin expression. Data presented in A), B) and 
C) are representative of at least two similar experiments.
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Page 7 of 14of double strand RNAs like PKR [25] and RIG1 [26]. The
TRIF protein was knocked out by RNA interference prior
to the treatment of Hela cells with poly(I:C). As shown in
Figure 3D, pre-treatment with TRIF-specific siRNAs
resulted in a complete abrogation of the increase in
BIRC3 transcription. Finally, to obtain a formal proof of
TLR3 involvement, its expression was knocked-down in
Hela cells, using 2 specific SiRNAs (Figure 4). One of
them did not achieve a complete silencing of TLR3: in
this context, an increase in c-IAP2 expression was still
detected under treatment by poly(I:C). In contrast, when
a complete extinction of TLR3 was obtained using a
stronger siRNA, there was no detectable increase in c-
IAP2 expression.
Figure 3 Treatment by poly(I:C) increases c-IAP2 gene (BIRC3) transcription in human malignant cells. Inhibition by Bafilomycin A1 and 
knock-down of TRIF. A) Cell concentrations of BIRC3 messenger RNAs are measured by quantitative RT-PCR in several types of malignant cells mock-
treated or treated with poly(I:C) for 16 h at 500 ng/ml. Concentration of BIRC3 transcripts measured in basal conditions were chosen as a reference for 
each tested cell type and arbitrarily set at 1. B) Kinetics of the increase in the concentration of BIRC3 messenger RNAs in HeLa cells treated with poly(I:C) 
500 ng/ml for increasing time intervals from 1 to 48 h. C) The influence of poly(I:C) on BIRC3 transcripts is neutralized by Bafilomycin A1, an inhibitor 
of endosome acidification and TLR3 signalling. Prior to RNA extraction, HeLa cells are incubated for two hours in the presence of poly(I:C)(500 ng/ml) 
or recombinant TNF α (20 ng/ml) in combination with Bafilomycin A1 (BFA) 100 nM or 2-aminopurin (2-AP) 5 mM or without additional compound 
(control condition). D) The induction of c-IAP2 by poly(I:C) in Hela cells is suppressed when the TRIF adaptor protein is knocked-down using 3 distinct 
specific siRNA whereas a non-specific (NS) RNA used as a negative control has no inhibitory effect. Upper panel: quantitative PCR assessment of the 
BIRC3 transcripts in the absence or in the presence of specific siRNAs. Lower panel: absence of TRIF protein expression detectable by western blot in 
Hela cells treated with specific siRNA (1, 2 and 3); in contrast TRIF expression is not altered by a negative control non-specific siRNA (NS). Data are rep-
resentative of two similar experiments. The stars indicate a statistical difference from respective controls (p < 0.05).
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Page 8 of 14An IAP inhibitor based on Smac mimicry (RMT 5265) 
cooperates with poly(I:C) in apoptosis induction
Poly(I:C) has been reported to induce apoptosis in several
cell types at high concentrations [5-7]. On the other hand,
the rise in c-IAP2 proteins and transcripts observed in
our experiments suggested that poly(I:C) was also acti-
vating anti-apoptotic pathways, especially pathways
involving the IAP family of proteins. We hypothesize that
inhibition of c-IAP2 expression could unmask the apop-
totic potential of TLR3 stimulation. To address this point
Skov3 cells (derived from an ovarian carcinoma) were
treated with siRNAs targeting either c-IAP2 or XIAP
(Figure 5). An increase in PARP cleavage was observed
when cells were treated with poly(I:C) following deple-
tion of either c-IAP2 or XIAP, providing evidence that c-
IAP2 as well as XIAP contribute to prevent TLR3-depen-
dent apoptosis. To investigate whether these results could
translate in a potential therapeutic strategy, we combined
poly(I:C) with a pharmacological inhibitor of the IAP
proteins, the Smac mimetic RMT 5265 (Figure 6A). Using
the T1 melanoma cell line, we found additive effects of
the combined treatment with a large increase in the sub-
G1 fraction as shown by flow cytometry (Figure 6B). In
the next experiment, cells from 5 tumor lines were
treated with a single agent - either poly(I:C) or RMT 5265
- or by a combination of both agents. Total activities of
caspases 3 and 7 were measured by a chemiluminescent
assay providing an index of apoptosis. Massive activation
of caspase 3/7 was obtained under the combined treat-
ment in 3 out of 5 malignant cell lines (SKOV3, ovarian
carcinoma, T1, melanoma and HeLa, Cervix carci-
noma)(Figure 7A, middle panel). Caspase 3/7 activation
was associated with degradation of the large PARP iso-
form (Figure 7A, lower panel). The effect of the combined
treatment was obviously more than additive for caspase
3/7 activation in Hela cells. In SKOV3 cells, RMT 5265 by
itself was sufficient for caspase 3/7 activation; however,
its activity was increased two-fold when the cells were
subjected to the combined treatment. A parallel increase
in caspase 8 activation was noticed in all three cell types
undergoing massive caspase 3/7 activation (Figure 7A,
upper panel). The cleavage of caspase 8 was formally
demonstrated by western blot analysis in Hela cells sub-
jected to the combined treatment (Figure 7B). There was
also mild apoptosis induction for IGR-OV1 with slight
enhancement of caspase 3/7 activity (Figure 7A). LNCaP
Figure 4 Knocking-down TLR3 suppresses enhancement of c-IAP2 protein expression by poly(I:C). Western blot analysis of protein extracts 
from HeLa cells treated with poly(I:C) (500 ng/ml for 16 h) with or without pre-treatment with TLR3-specific and control (NS) siRNAs. The same mem-
brane was stained successively with anti-c-IAP2, TLR3 and β-actin. Note that the control siRNA by itself enhanced TLR3 and c-IAP2 expression. This is 
consistent with previous observations and possibly related to the interaction of these small double-strand RNAs with the TLR3 itself regardless of their 
sequence [36]. In our transfection protocol siRNAs are at 100 nM for the first 4 h and 50 nM for the next 44 h. TLR3 inhibition was not complete with 
the siRNA n°1 which was apparently weaker than the siRNA n°2. However the siRNA n°1 was strong enough to prevent enhancement of TLR3 and c-
IAP2 expression in the absence of poly(I:C). Data are representative of two similar experiments.
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Page 9 of 14was the only cell line without any evidence of apoptosis
induction under the combined treatment. Simultaneously
c-IAP2, c-IAP1, XIAP and FLIP-L cell concentrations
were assessed in these various experimental conditions
by western blotting (Figure 7A, lower panel). Poly(I:C)
stimulation induced a strong increase of c-IAP2 concen-
trations in all cell lines, as shown in previous figures.
Treatment with RMT 5265 resulted in a dramatic reduc-
tion of c-IAP2 and to a lesser extent c-IAP1 when used
alone as well as in combination with poly(I:C). This was
observed in all cell lines except IGR-OV1. A reduction of
FLIP-L was recorded in several experimental conditions,
especially under the combined treatment. XIAP concen-
tration was reduced in cells undergoing massive apopto-
sis under the combined treatment.
Cooperation of poly(I:C) and RMT 5265 in the inhibition of 
clonogenic growth for various types of human malignant 
cells
To further explore the anti-tumor potential of the combi-
nation of poly(I:C) with RMT 5265, several cell types -
IGR-OV1, T1, Hela, LNCaP and NP69 - were seeded at
low density and grown in the presence of single agents or
the combination of both (Figure 8). Poly(I:C) and RMT
5265 had virtually no effects on the non-tumorigenic
NP69 cells. In contrast a highly significant reduction of
clone numbers were obtained for cells undergoing mas-
sive apoptosis under the combined treatment, HeLa and
T1. A similar reduction of clonogenic growth was
observed for IGR-OV1 cells. Although there was no evi-
dence of apoptosis induction in LNCaP, there was a mild
but statistically significant reduction of its clonogenic
growth under the combined treatment.
Discussion and Conclusions
The aim of this study was to explore the contribution of
the IAP family of proteins to the response of cells chal-
lenged by the synthetic TLR3 agonist poly(I:C). Our two
main findings are a rapid and often dramatic increase in
c-IAP2 protein concentration following poly(I:C) stimu-
lation and a cooperative effect of poly(I:C) with the IAP
inhibitor RMT 5265 in the induction of apoptosis and/or
inhibition of clonogenic growth
The increase in c-IAP2 protein concentration triggered
by poly(I:C) has several interesting characteristics. It is
constant through all types of human malignant cells
tested, including cells directly explanted from fresh
tumors. So far we have found no exception to this type of
response. Even in NPC cells which have very high consti-
tutive levels of c-IAP2, we found that stimulation by
poly(I:C) further increases its expression (Friboulet et al.,
2008 and data not shown). However poly(I:C) does not
induce any increase in c-IAP2 concentration in two types
of non-tumorigenic human cell lines - NP69 and MRC5 -
suggesting that this modification is restricted to fully
transformed cells. Finally, the increase in c-IAP2 expres-
sion has a double specificity. With regard to the TLR fam-
Figure 5 Enhanced apoptosis in Skov3 ovarian carcinoma cells treated with poly(I:C) combined with knocking-down c-IAP2 or XIAP. Skov3 
cells were pre-treated with non-specific (NS), c-IAP2 or XIAP siRNAs with or without subsequent addition of poly(I:C). Cell protein extracts were sub-
jected to western blot and stained successively for c-IAP2, XIAP, PARP and tubulin-α. PARP-cleavage was substantially enhanced by combination of 
poly (I:C) with c-IAP2 and XIAP siRNAs.
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Page 10 of 14ily of receptors, it is induced by the TLR3 ligand poly(I:C)
but not by ligands of other TLRs for example TLR-9
ligands (Figure 2B). With regard to the IAP family of pro-
teins, although c-IAP1 and c-IAP2 expression are often
co-regulated, poly(I:C) has no effect on c-IAP1 expres-
sion [27].
In all tumor cell lines but one, the increase in the c-
IAP2 protein expression which occurrs under treatment
by poly(I:C) is, at least to a large extent, related to an
increase in the c-IAP2 gene (BIRC3) transcription. In this
regard, the ovarian carcinoma cell line Skov3 is an excep-
tion. It has an increase in the expression of the c-IAP2
Figure 6 Induction of apoptosis in T1 cells treated with poly(I:C) combined with a smac-mimetic (RMT 5265). A) Representation of the RMT 
5265 molecule backbone drawn with MARVIN online software: http://atchimiebiologie.free.fr/marvin/doc/dev/oli.html. Substitution of one H on both 
alanines (R = CO2Bu-t) results in an inactive compound used as a negative control (HS4044). B) Flow cytometry assessment of the sub-G1 cell fraction 
in the T1 cell line treated with control compound or RMT 5265 (100 nM; 48 h) with or without poly(I:C)(500 ng/ml; last 16 h).
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Figure 7 Analysis of biochemical changes in human malignant cell lines treated with poly(I:C) combined to RMT 5265. A) Cell samples rep-
resentative of five different cell lines were subjected to the following treatments: control compound or RMT 5265 (100 nM for 48 h) with or without 
poly(I:C) (500 ng/ml; last 16 h). Caspase 3/7 (middle panel) and caspase 8 (upper panel) activities were measured in cell protein extracts using a chemi-
luminescent assay. c-IAP2, c-IAP1, FLIP-L and β-actin were detected in additional cellular extracts from the same experimental samples by western 
blotting using specific antibodies applied successively to the same blotted membrane (lower panel). The stars indicate a statistical difference from 
respective controls (p < 0.05). B) Western blot analysis of caspase-8 cleavage in HeLa cells treated with control compound or RMT 5265 (200 nM for 
48 h) with or without poly(I:C) (1 μg/ml; last 16 h). In order to provide a positive control for caspase 8 cleavage, HeLa cells were treated with TNF-α (50 
ng/ml) plus cycloheximide (2.5 μg/ml) for 6 h. The same blotted membrane was stained with anti-tubulin-α for protein loading control.
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Figure 8 Impact of poly (I:C) and RMT 5265 on the clonogenic growth of human cell lines. Cells from IGR-OV1, T1, HeLa, LNCap and NP69 cell 
lines were seeded at low densities in 6 well-plates as reported in the Methods section. A) Plates were stained with crystal violet after 2 to 3 weeks of 
growth. B) Colonies were counted after scanning and digitalization of dried plates (Epson perfection 4990 scanner). For star-marked conditions, the 
differences in colony numbers with the control condition were statistically significant (p < 0.05).
A
Control 
agent
100nM
RMT5265
100nM
NP69
Control 
agent + 
Poly(I:C) 
500ng/ml
RMT5265 + 
Poly(I:C) 
500ng/ml
IGR-OV1
HeLa
B
0
20
40
60
80
100
120
140
IGR-OV1 T1 HeLa LNCaP NP69
Co
lo
ny
 
n
u
m
be
r (
ra
tio
)
control agent
RMT5265
control agent + Poly(I:C)
RMT5265 + Poly(I:C)
*
* *
*
*
*
*
Friboulet et al. BMC Cancer 2010, 10:327
http://www.biomedcentral.com/1471-2407/10/327
Page 13 of 14protein without a significant increase in the amount of
the corresponding messenger RNA. The change observed
at the protein level might result from a mechanism
improving translation efficiency - "ribosome shunt" - as
previously reported, precisely in a model involving c-
IAP2 messenger and protein [28]. This hypothesis would
deserve specific future investigations. In any event, we
obtained compelling evidence that the changes in c-IAP2
expression observed in Hela cells treated with poly(I:C)
are dependent on the activation of the TLR3/TRIF path-
way. Indeed, the increase in BIRC3 transcription is com-
pletely abrogated by Bafilomycin A1 - a chemical agent
known to block TLR3 signalling at the endosome level -
as well as by knocking-down expression of the TRIF
adaptor. Moreover, knocking-down TLR3 itself abrogates
the increase in c-IAP2 expression. Currently, we have no
idea whether NF-KB or interferon-β contribute to
enhanced expression of the c-IAP2 gene downstream of
TRIF. Nevertheless, in future studies, the increase in c-
IAP2 expression is likely to provide a novel and sensitive
index of malignant cell response to TLR3 stimulation.
Cell treatment combining RMT 5265 with poly(I:C)
induces massive apoptosis in 3 of 5 malignant cell lines,
with obvious synergy of the 2 compounds in two cases.
Apoptosis induction is associated with decreasing cell
concentrations of c-IAP2, c-IAP1, XIAP and FLIP-L.
RMT 5265 like other smac mimetics is known to induce
degradation of c-IAP2 and to a lesser extent c-IAP1
through ubiquitinylation and proteasome degradation
[14,15]. Therefore we suspect that the decrease in c-IAP1
and c-IAP2 is an early drug-induced event with a possible
causative role in the induction of apoptosis in T1 and
HeLa cells. However, despite a dramatic decrease in c-
IAP2 concentration and the absence of c-IAP1 expression
in LNCaP cells, massive apoptosis is not induced by the
combined treatment suggesting that other signalling
events are required. c-IAP2 and c-IAP1 are not degraded
in IGR-OV1 cells under treatment by RMT 5265. So far,
in our experience, there is no other example of a cell line
where c-IAP2 and c-IAP1 are resistant to degradation
induced by RMT 5265. Nevertheless, we cannot exclude
that they are functionally inactivated by RMT 5265 in
IGR-OV1 cells. XIAP is usually not degraded by RMT
5265, therefore its decrease in SKOV3, HeLa and T1 cells
is probably a consequence of massive apoptosis resulting
from its digestion by executionary caspases [29]. So far
we have no explanations for the decrease of Flip-L
observed in several cell types under the combined treat-
ment. In each of the 3 cell lines undergoing massive apop-
tosis, caspase 8 activation is prominent suggesting its
critical role in the initiation of the process. Consistently,
while this manuscript was in preparation, a recent publi-
cation has reported caspase 8 activation in melanoma
cells subjected to a combination of poly(I:C) with a smac
mimetic [30]. Involvement of caspase 8 is not surprising
since RIP1, a major regulator of caspase 8 is under indi-
rect control of TLR3 and c-IAP2. TLR3 stimulation acti-
vates RIP1 in a TRIF-dependent manner [31]. In the
presence of c-IAP2, RIP1 is expected to activate the
canonical NF-kB pathway whereas in the absence of c-
IAP2, it will switch to caspase 8 activation [13,32-34].
Verification of this hypothetical mechanism will require
further investigation.
The combination of poly(I:C) and RMT 5265 inhibits
clonogenic cell growth in all 3 cell lines for which it
induces apoptosis. In addition, clonogenic growth was
also inhibited in the ovarian carcinoma cell line IGR-OV1
suggesting that the combined treatment has cytotoxic
effects even in the absence of massive apoptosis induc-
tion. In contrast, the combined treatment has almost no
effects on the non-transformed epithelial cell line NP69.
This observation raises hope that synthetic TLR3 ligands
combined to IAP inhibitors might have selective effects
on malignant cells. One basis for this selectivity might be
related to the status of TLR3 in malignant cells. In this
regard it is interesting to observe a much greater positive
feed-back of poly(I:C) on TLR3 expression in most malig-
nant cells compared to MRC5 and NP69 (Figure 1B). In
other words, TLR3 seems to be either more abundantly
expressed or more "responsive" in fully transformed cells
than in non-tumorigenic cells. A point that will need to
be addressed in both biological and clinical studies.
Assessing in cancer patients the selectivity and efficiency
of TLR3 ligands combined to IAP inhibitors is a reason-
able aim since both types of compound are already under
phase II or III clinical trials [4,35].
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